Market Data 
Markets
Replies to post #2271 on Quanta Inc (fka QNTA)
05/14/21 6:18 AM
05/14/21 8:40 AM
05/14/21 9:03 AM
05/27/21 1:17 PM
06/03/21 3:33 PM
QNTA merger news: BURBANK, May 11, 2021 (GLOBE NEWSWIRE via COMTEX) -- BURBANK, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire ??' Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today its President Philip Sands will be stepping down from the position, completing the planned final step in the merger with Quanta. Stepping into his place, Medolife CEO Dr. Arthur Mikaelian will act as the interim President and Chairman of the Board, while continuing in his role as CEO.
"We are excited to have completed this transition, which was one of the final steps in completing the merger of Medolife into Quanta, forming our new company Medolife Rx," said Medolife CEO Dr. Arthur Mikaelian. "We have been working very hard to align the pieces necessary to ensure our success as a global pharmaceutical and nutraceutical company, and this marks a new moment in the company's future."
"Our opportunity has never been greater, and we appreciate those who continue to follow our Company and believe in our future," added Dr. Mikaelian.
Medolife Rx, Inc. is a global biotechnology company with operations in clinical research, manufacturing and consumer products. Medolife Rx was created through the merger of Medolife, a private company founded by Dr. Mikaelian who pioneered the underlaying polarization technology that makes the Company's portfolio of pharmaceutical and nutraceutical products so effective, and Quanta, Inc., a direct-to-consumer wellness product portfolio company. The Company's lead clinical development programs include Escozine(R), a proprietary formulation consisting of small molecule peptides derived from Rhopalurus princeps scorpions, which is amplified by the Company's polarization technology and is being researched as a treatment for various indications, including the SARS-CoV-2 (COVID-19) virus and cancer. The Company has completed preclinical safety and efficacy research on Escozine(R) and recently announced product registration in the Dominican Republic (DR), allowing for sales of Escozine(R) throughout Latin America.
Furthermore, the Company will continue to operate in the nutraceutical space with consumer products in general wellness, sleep-aid, anxiety treatment, and pain management.
$QNTA
06/03/21 3:37 PM
BusinessWire, GlobeNewswire and PR Newswire News
Quanta Inc QNTA:OTC Pink - Current Information
Medolife Rx Schedules Investor Webcast for Tuesday June 8, 2021
GlobeNewswire
2:36 PM ET
via NewMediaWire -- Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today that it will hold a webcast with the investment community on Tuesday, June 8, at 5 p.m. Eastern Daylight Time.
On the webcast, Medolife CEO Dr. Arthur Mikaelian and Chief Financial Officer Clemente Pascarella will discuss recent happenings with the company. To register for this webcast, please use the below web link.
https://zoom.us/webinar/registe r/WN_qIvaZL5-T3C5_buGoXxpTw
If you have questions, please send an email to medolife@cmwmedia.com with 'QNTA Question' in the subject line by 6 p.m. Eastern Daylight Time on Monday, June 7. Dr. Mikaelian and Mr. Pascarella will answer as many questions as time will allow. For those unable to participate in the live webcast, an archived version of the webcast will be available in the following days.
About Medolife Rx
Medol ife Rx, Inc. is a global biotechnology company with operations in clinical research, manufacturing, and consumer products. Medolife Rx was created through the merger of Medolife, a private company founded by Dr. Arthur Mikaelian who pioneered the unlaying polarization technology that makes the Company's portfolio of pharmaceutical and nutraceutical products so effective, and Quanta, Inc., a direct-to-consumer wellness product portfolio company. The Company's lead clinical development programs include Escozine(R), a proprietary formulation consisting of small molecule peptides derived from Rhopalurus princeps scorpions, which is amplified by the Company's polarization technology and is being researched as a treatment of various indications, including COVID-19 and cancer. The Company has completed preclinical safety and efficacy research on Escozine(R) and is pursuing product registration and drug approval in various countries, including the United States and throughout Latin America.
Through its subsidiary QuantRx, Medolife manufactures and distributes consumer wellness products in high-impact consumer areas such as pain relief, beauty, and general wellness. QuantRx products are designed using Dr. Mikaelian's polarization technology, which applies advances in quantum biology to increase the potency of active ingredients. Ultimately, Quanta's mission is to deliver better, more effective ingredients to elevate product efficacy, reduce waste, and facilitate healthier, more sustainable consumption.
Beyond its own clinical and consumer applications, the polarization technology used by Medoli fe and its subsidiaries has many potential applications. From potentiating bio-ingredients, to producing more-effective carbon-trapping plants, to transformative anti-aging solutions, Medolife has the opportunity to upend how commercial and pharmaceutical products are made and increase their benefits, while decreasing their chemical concentration.
Forward-Looking Statements
Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995: This release contains statements that are forward-looking in nature which express the beliefs and expectations of management including statements regar ding the Company's expected results of operations or liquidity; statements concerning projections, predictions, expectations, estimates or forecasts as to our business, financial and operational results and future economic performance; and statements of management's goals and objectives and other similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "we believe," "we intend," "may," "will," "should," "could," and similar expressions. Such statements are based on current plans, estimates and expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. These factors and additiona l information are discussed in the Company's filings with the Securities and Exchange Commission and statements in this release should be evaluated in light of these important factors. Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
Contacts:
Tom Nelson
https://ir.quantrx.com/
818-659-8052
Kyle Porter
medolife@cmwmedia.com
858-264-660 0
__GNW8366DE3E__IMG
__GNW8366DE3E__IMG
COMTEX_387802790/2010/2021-06-03T14:36:31
06/07/21 9:01 AM
Quanta, Inc. (QNTA) Basic Due Diligence Package
Medolife Rx was created through the merger of Medolife, a private company founded by Dr. Arthur Mikaelian who has completed all research and the development process and has attained the legal registration to commercialize the Blue Scorpion venom based product under the name of Escozine.
https://medolife.com/
Escozine™ was originally developed and commercialized by Medolife, Corp. in 2007. Until 2007, this natural medicine has only been available in Cuba, where it is known as Escozul. Medolife currently holds the exclusive patent license, (United States patent # 8,097,284 B2) of the bioactive peptide and polarization technology used to make the Polarized Dilute Blue Scorpion Venom. Escozine™, is registered and certified for oncological treatment by the Minister of Health in the Dominican Republic. Escozine™ is currently distributed in six countries (Dominican Republic, Vietnam, Russia, Belarus, Nigeria and Kazakhstan).
Escozine has been used for years to treat humans with cancer in many countries and its positive results are backed by numerous scientific research, pre-clinical and clinical observations that confirm its safety and efficacy.
Medolife has been successfully marketing its Escozine products through direct sales in 40 countries. Medolife has invested over $10 million in R&D in Escozine (for humans) over 10 years and amassed substantial scientific documentation, worldwide of its effectiveness.
CLOSER TO FDA APPROVAL, for its Pre-Investigational New Drug (PIND #150335) filing on its lead drug candidate Escozine® as a COVID-19 therapeutic. May 13th marks 30 days since the application.
06/09/21 10:04 AM
https://ir.quantrx.com/company-information/management-team
QUOTE:
"Khalid Matalka, Ph.D., SI(ASCP)
Chief Scientific Officer
Professor Khalid Matalka received his BSc and MSc in Medical Technology in 1986 and 1988 from Yarmouk University, Jordan, and the University of Wisconsin-Milwaukee, USA. Then he received his Ph.D. in Pathology (Immunology and Cancer therapy) from Ohio State University, USA, in 1992.
After finishing his Ph.D., Dr. Matalka joined Harvard Medical School as a Postdoctoral fellow till 1994. He is an American Board Certified as a Specialist in Immunology (SI-ASCP) and a member at the American Society for Cancer Research since 1994.
Dr. Matalka enrolled in academia as an assistant professor in 1995, then promoted to associate and then a professor in 2004. Prof. Matalka held a dean position at two different academic institutions. Besides, Prof. Matalka was a consultant for twenty years to a JPM pharmaceutical company and a hospital diagnostic laboratory.
During those 22 years, Prof. Matalka was heavily involved in research mainly on immunomodulation, cancer research, and development of immunological assays. In 2016, he joined a pharmaceutical startup company named OncoTherapeutica, MA as a Chief Biologist.
While there, Prof. Matalka was developing new potential drugs for the treatment of prostate cancer and melanoma. In March 2020, Prof. Matalka joined Medolife Corporation as Chief Scientific Officer (CSO) and, in February 2021, became the CSO of the newly established Medolife Rx.
Prof. Matalka has 65 publications in peer-reviewed international journals, and he is an Associate Editor of two and a member of the editorial board of several international journals.
Prof. Matalka is known as an international reviewer in the fields of Cancer therapy, Immunomodulation, and Ethnopharmacology.
"
NIiiiiiice and WOW !!
FDA is going to sit-up and take this dude seriously when HE SUBMITS and SIGNS THEIR IND APPLICATIONS and CLINICAL DATA REPORTS etc !
HARVARD MED - among other top shelf name droppers and 65 PEER REVIEW journal pubs = BIG HITTER TERRITORY !!
06/17/21 10:36 AM
AI
